Results 91 to 100 of about 204,987 (288)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Modeling immune checkpoint inhibitor associated myocarditis in vitro and its therapeutic implications

Journal of Molecular and Cellular Cardiology Plus
Immune checkpoint inhibitor-associated myocarditis is the most lethal side effect of immune checkpoint blockade. Myocarditis leads to persistently increased mortality and lacks effective treatments.
Garrett Jensen, Xinjie Wang, Jacob Kuempel, Zhishi Chen, Wei Yu, Nicolas Palaskas, Mary Sobieski, Nghi Nguyen, Reid T. Powell, Clifford Stephan, Weijia Luo, Jiang Chang   +11 more
doaj   +1 more source

Immune Checkpoint Inhibitor-Induced Myasthenia Gravis

Frontiers in Neurology, 2020
The development of immune checkpoint inhibitors (ICIs) has been a major breakthrough in cancer immunotherapy. The increasing use of ICIs has led to the discovery of a broad spectrum of immune-related adverse events (irAEs).
Yi-Te Huang, Ya-Ping Chen, Wen-Chih Lin, Wu-Chou Su, Yuan-Ting Sun, Yuan-Ting Sun   +5 more
doaj   +1 more source

Immune Checkpoint Inhibitor-Related Pneumonitis

Respiration, 2020
Immune checkpoint inhibitors are novel agents that have been proved efficacious in a variety of cancer types, but they are associated with a unique set of organ-specific, immune-related adverse events. Among them, immune-related pneumonitis requires special attention because it is difficult to diagnose and potentially lethal.
Gomatou, G., Tzilas, V., Kotteas, E., Syrigos, K., Bouros, D.   +4 more
openaire   +3 more sources

Combination Therapies of Guadecitabine and Immune Checkpoint Inhibitors in a Murine Triple-Negative Breast Cancer Model [PDF]

, 2020
Combination Therapies of Guadecitabine and Immune Checkpoint Inhibitors in a Murine Triple-Negative Breast Cancer Model Jamie-Jean Gilmer, Depts. of Biology and Chemistry, with Dr. Sarah Golding, Dept.
Gilmer, Jamie-Jean
core   +1 more source

New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. [PDF]

, 2018
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. HCC initiates as a consequence of chronic liver damage and inflammation caused by hepatitis B and C virus infections, excessive alcohol consumption, or non ...
Karin, Michael
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer. [PDF]

, 2016
Renal cell carcinoma (RCC) is increasing in incidence, and a complete cure remains elusive. While immune-checkpoint antibodies are promising, interferon-based immunotherapy has been disappointing.
Abu Aboud, Omran, Anderson, Katie, Berryhill, Grace, Chen, Ching-Hsien, Graef, Ashley, Hovey, Russell C, Kim, Jeffrey, Modiano, Jaime F, Sarver, Aaron L, Stewart, Benjamin, Trott, Josephine F, Uzal, Francisco, Weiss, Robert H, Wettersten, Hiromi   +13 more
core   +2 more sources

Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer

FEBS Open Bio, EarlyView.
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold, Janik Riese, Lancelot Seillier, Mark Kühnel, Julia Pannhausen, Charlotte O. J. Fröhlich, Christian Martin, Peter Boor, Matthias Saar, Danny D. Jonigk, Nadine T. Gaisa, Michael Rose   +11 more
wiley   +1 more source

Immune Checkpoints in Cancer Treatment [PDF]

, 2018
Despite the human immune system, cancer thrives in an extremely hostile environment. Cancer is the second most common cause of death in the U.S. with about 600,000 deaths every year, and cancer is expected to surpass heart disease as the most common ...
Cherubino, Matthew A.
core   +1 more source